Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma

Baldin, A.V.; Grishina, A.N.; Korolev, D.O.; Kuznetsova, E.B.; Golovastova, M.O.; Kalpinskiy, A.S.; Alekseev, B.Y.; Kaprin, A.D.; Zinchenko, D.V.; Savvateeva, L.V.; Varshavsky, V.A.; Zernii, E.Y.; Vinarov, A.Z.; Bazhin, A.V.; Philippov, P.P.; Zamyatnin, A.A.

Авторы: Baldin Alexey V., Grishina Alena N., Korolev Dmitry O., Kuznetsova Ekaterina B., Golovastova Marina O., Kalpinskiy Alexey S., Alekseev Boris Y., Kaprin Andrey D., Zinchenko Dmitry V., Savvateeva Lyudmila V., Varshavsky Vladimir A., Zernii Evgeni Yu, Vinarov Andrey Z., Bazhin Alexandr V., Philippov Pavel P., Zamyatnin Andrey A.
Журнал: Biochimie
Том: 157
Год издания: 2019
Издательство: Elsevier BV
Местоположение издательства: Netherlands
Первая страница: 26
Последняя страница: 37
DOI: 10.1016/j.biochi.2018.10.019
Аннотация: Renal cell carcinoma (RCC) is the second-most common uronephrological cancer. In the absence of specific symptoms, early diagnosis of RCC is challenging. Monitoring of the aberrant expression of tumour-associated antigens (TAAs) and related autoantibody response is considered as a novel approach of RCC diagnostics. The aim of this study was to examine the aberrant expression of arrestin-1 in renal tumours, to investigate the possible epigenetic mechanism underlying arrestin-1 expression, and to assess the frequency of anti-arrestin-1 autoantibody response. Immunohistochemistry was used to assess the presence of arrestin-1 in primary tumours and metastases of 39 patients with RCC and renal oncocytoma. Bisulfite sequencing was employed to analyse the methylation status of the promoter of the SAG gene encoding arrestin-1. Western blot analysis was performed to detect autoantibodies against arrestin-1 in serum samples of 36 RCC and oncocytoma patients. Arrestin-1 was found to be expressed in RCC (58.7% of cases) and renal oncocytoma (90% of cases) cells, while being absent in healthy kidney. The expression of arrestin-1 in RCC metastases was more prominent than in primary tumours. Hypomethylation of the SAG gene promoter is unlikely to be the mechanism for the aberrant expression of arrestin-1. Autoantibodies against arrestin-1 were detected in sera of 75% of RCC patients. Taken together, our findings suggest employment of autoantibody against arrestin-1 as biomarker of RCC.
Добавил в систему: Зерний Евгений Юрьевич

	ИСТИНА	Войти в систему Регистрация
	ФНКЦ РР
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ФНКЦ РР

Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinomaстатья Исследовательская статья